HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Health & Nutrition Systems International expects to book revenue by the end of March from its January acquisition of three Acutrim trademarks and outstanding inventory of two natural "ephedrine-free" appetite suppressant formulations for $180,000 from Heritage Brands/Insight Pharmaceuticals. West Palm Beach, Fla.-based HNS, which markets weight management and body building products such as Carb Cutter, Thin Tab and Carbolizer in gyms, health food stores and drug chains, purchased only the inventory for Acutrim Natural A.M. and P.M., which launched last June (1"The Tan Sheet" May 15, 2000, p. 7). Heritage pulled original Acutrim formulas from the market after FDA's November request that companies voluntarily halt marketing PPA-containing products. The Acutrim franchise has lost market share in recent years to ephedrine alkaloid-containing supplements

You may also be interested in...

Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned

Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.

Acutrim, Allerest Extensions Focus On Natural Ingredients

New Acutrim Natural, a "dietary supplement and weight loss system" extension to the appetite suppressant line, contains no ephedrine, is drug-free and causes no side effects, according to marketer Heritage Consumer Products.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts